• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Reed-Lane

    Baxter BioPharma Solutions

    Alcami

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Adare Pharma Solutions

    Emergent BioSolutions

    Baxter BioPharma Solutions

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Bio-Growth Slowing?

    A new report details bio-outsourcing trends in 2012

    Related CONTENT
    • Oakwood Labs
    • Mogene
    • Taros Chemicals
    • Sekisui
    • Vetio Animal Health
    Eric Langer, BioPlan Associates05.04.12
    Outsourcing has been a major trend in recent years, and the broad industry developments continue to favor increased biopharma outsourcing. However, our 9th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production1 confirms a number of trends related to outsourcing. This year’s survey was based on responses from 302 biopharmaceutical industry professionals from 29 countries. Overall, the study indicates
    that outsourcing continues to increase, but spending is leveling off, and industry attitudes and the execution of outsourcing appear to increasingly be more sophisticated, strategic and better planned (as opposed to being areas for reflexive cost-cutting).

    Trends include the continued and accelerating emphasis of large international Big Bio/Pharma companies (those collectively responsible for ≥90% of industry R&D and sales (see www.top1000bio.com2)), on increasing involvement in development of biopharmaceuticals, and the coming of biosimilars. Already, ≥40% of the overall pharmaceutical R&D pipeline is reported to involve biologics (vs. small molecule drugs), and this expected to eventually reach 50%. Compared to drugs, biologics offer more specificity and reduced toxicities; associated with this, they have a higher success rate in clinical trials and attaining approvals, have higher sales per unit (the products cost much more), often with fewer sales involved, and higher profit margins.

    Biosimilars
    Biosimilars are finally coming to the U.S. market, with FDA having issued its first guidelines in early 20123. This event means the bio-outsourcing industry landscape will likely change. Contract manufacturer organizations (CMOs) will be among the recipients of benefits from biosimilars (and the related category of biobetters). In coming years, as data and market exclusivities and patents expire on the majority of the first decades’ worth (1980s-1990s) of recombinant proteins, we can expect multiple — perhaps, five to 10 or even more — biosimilar (and biobetter) versions of every successful established product to enter the U.S. and world markets. Many manufacturers may shift their legacy off-patent products to CMOs, while devoting in-house manufacturing capacity to newer, innovative, higher-profit products. Many dozens of new biosimilar developers will require manufacturing capacity for a growing number of products. Because most biosimilar developers are smaller companies, they often lack manufacturing infrastructure and expertise, and with biosimilar markets being relatively small (compared to the established products they target), a large proportion of biosimilar developers will find benefit in the use of CMO services. There are relatively few CMOs with actual commercial bio-manufacturing experience, but that will increase. Biosimilars will also result in growth in use of other outsourced services, including analytical data and bioassays, with this perhaps starting to be evident in our survey data.

    Standardizing
    Standardization of manufacturing is another trend supporting outsourcing. Particularly within larger companies, as more biopharma manufacturing is performed to support worldwide markets, companies are working to standardize their products and manufacturing processes on a worldwide basis. This includes having second- or even third-source facilities either actively manufacturing or serving as back-ups. In some cases, it can be more cost-effective to hire and transfer a process to a CMO as an additional or backup manufacturer.

    Mergers
    Outsourcing trends are also being driven by corporate mergers and acquisitions, which tend to be directed to improving R&D pipelines rather than cost-savings from facility consolidations and lay-offs. Associated with this, many large companies are now directing more attention to acquiring smaller companies and in-licensing candidate products. Partnering has intensified as large pharma and biopharma companies execute strategic initiatives toward better R&D and products, with most established biologics facing patent cliffs and increased competition from biosimilars, biobetters and other off-patent follow-on products.

    Slowing and Becoming More Strategic
    Outsourcing, including R&D and contract manufacturing, continues to be a major trend. However, our study data indicate that the rate of outsourcing is slowing, with prior increases in funding of outsourcing tending to level off. With this phenomenon, it appears that contract manufacturing will not be the primary manufacturing approach in the future, as it would be if prior high growth in outsourcing of manufacturing were to continue without slowing.






























    Companies of all sizes that formerly outsourced a majority of feasible processes are now taking a more rational approach — carefully evaluating and weighing options, including looking at outsourcing from a longer-term and strategic perspective. There appears to be a slowing of what often seemed to cost-directed cuts: downsizing, lay-offs and closing and divestment of in-house corporate capabilities. Perhaps, this longer-term outlook is enabled by improved economic conditions. We note that our survey data show 70% of biopharma companies outsourcing at least some activity.

    Outsourcing to emerging markets continues, including Asia and Eastern Europe, but is slowing and reaching its limits, with outsourcing of R&D outpacing that of manufacturing. Eventually, bio-manufacturing will start to be significantly outsourced to lesser-developed countries, although it will likely be many years, perhaps a decade, before a significant number of U.S./EU biologics are manufactured in developing countries. No major trend has yet developed of companies outsourcing clinical or commercial manufacturing to lesser-developed countries. At the moment, developing countries lack the needed critical mass of facilities, knowledgeable and cGMP-experienced staff, information and quality systems, institutional know-how, business culture and ethics required for full U.S./EU cGMP biopharma manufacture. We can expect increased use of developing country-based CROs and also CMOs, but primarily to support pre-commercial R&D and product testing.

    Industry Outsourcing Budget Trends
    This year, we see evidence of slowing in outsourcing budgets, albeit with further increases planned. This includes responses showing a current leveling-off of outsourcing budgets. For 2012, the average reported outsourcing budget change was down a miniscule (within margin of error) 0.4%, with other increases and decreases in the past few years remaining within +/- 1.5%. By this measure, recent years’ budget increases for outsourcing have leveled off or stalled. When asked to identify actions taken in the past year to reduce costs, an increased percentage, 14.5% (vs. 11.8% last year), cited outsourcing of jobs in manufacturing (while process development and R&D outsourcing remained steady); 9.4% cited outsourcing of manufacturing to domestic CMOs, up from 7.1% last year; and 9.4% cited outsourcing of manufacturing to foreign CMOs, up from 5.7% last year. Overall, outsourcing of manufacturing to domestic and non-domestic service providers (offshoring) involved only a small percentage of respondents (9.4%), indicating that there is still much capability for industry to expand its outsourcing of manufacturing to CMOs.

    Outsourcing budgets my not have increased this year, but companies broadly expect to increase their future outsourcing, including for manufacturing. This year among respondents manufacturing using mammalian cell culture, 47% indicated they performed all their production “in-house,” meaning that 53% outsource some product manufacturing. During the past few years, the percentage of developers doing all of their mammalian cell production “in-house” has shifted down slightly from 55.6% in 2006 to 57% in 2010, to 45% last year and 47% this year.

    For microbial fermentation, 50.0% of this year’s respondents indicated they performed all their production “in-house” (vs. 43.8% last year, 64.2% in 2010 and 58.1% in 2009). These and other data indicate an upcoming trend toward further outsourcing to CMOs. In contrast with these well-established manufacturing platforms, newer insect and plant cell culture platforms tend much more to be performed in-house.

    When asked about outsourcing plans through the next five years (2017), overall results indicate a continuing trend towards greater outsourcing of manufacturing, with a majority of mammalian (58.2%) and even higher percentage of microbial systems user (72.2%; 59.6% last year) projecting some outsourcing by 2017. Microbial manufacturing is the area currently with the highest proportion now outsourced and is the highest future growth area for outsourcing.

    Currently Outsourced Tasks
    While manufacturing gets much of the attention due to it being a critical and, by far, the single highest outsourcing expense, industry outsourcing projects continue to be dominated by relatively lower value-added services, such as fill-finish, product characterization and other testing. Our study this year shows that the primary outsourced activity remains analytical testing/bioassays, with more than 80% of companies outsourcing at least some of this activity, followed by validation services (69.8%). Testing/product characterization (65.6%) and fill-finish (63.5%) are next on the list of 24 outsourcing activities. The area with the largest growth in response this year was analytical testing/bioassays, with biosimilar development perhaps contributing to this. At the other end of the scale, the lowest rates for outsourcing activity were for Design of Experiments, downstream and upstream process development and operations, and QbD initiatives. These tasks are apparently considered core corporate capabilities not suitable to being outsourced.

    Growth in the Future
    When asked what activities will see “significantly higher” outsourcing in the next two years, 35.4% cited outsourcing of analytical testing/bioassays. This was up significantly in terms of the industry’s perspective on the area’s growth potential, from 18.3% last year. In addition, 32.3% noted validation services would be a hot growth area, up from 22.1% last year. Other areas of projected significant growth include fill-finish operations, manufacturing, cell line development, testing for lot release, and toxicity testing. When asked how their spending on outsourcing will change over the following 12 months, budgets for outsourcing at individual facilities will increase by 9.3% on average. Only 7.1% reported expecting any decrease in outsourcing!

    However, outsourcing is not without its problems. Separately, when CMOs were asked to cite common mistakes made by clients, 86.1% responded, “Clients don’t build in sufficient time for the project (unrealistic timeframes),” and, “Clients want to contain cost by limited development runs, but still expect successful full scale manufacturing.” So, communications and infeasible performance expectations remain common problem areas when using CMOs.

    The biopharma industry has survived the worldwide economic downturn of recent years and has even done rather well during this period. The biopharma industry has continued to grow at a steady pace and is now showing clear signs of further recovery and growth. Our survey data show that companies are now or are planning to spend and invest more in every budget area surveyed, including R&D and bioprocessing capacity, staff and other infrastructure. Larger and more established companies in particular are continuing to aggressively look for opportunities to cut costs and increase efficiency, with this continuing to benefit CMOs and CROs.

    Sponsor companies are generally outsourcing more selectively and with more long-term strategic considerations. They are now much more knowledgeable, experienced and comfortable with managing outsourcing, including evaluating related impacts, and judging related cost-effectiveness and strategic value. Widespread layoffs and elimination of formerly essential facilities, with these functions outsourced, has slowed. New products and new markets, particularly internationally, continue to support market opportunity and potential for growth in outsourcing.  

    References
    1. Langer, E., 9th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, BioPlan Associates, in press, approx. 500 pages, 2012.
    2. BioPlan Associates’ www.top1000bio.com
    3. Biosimilars.com, at www.biosimilars.com


    Eric S. Langer is president and managing partner at BioPlan Associates, Inc. (www.bioplanassociates.com), a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including Biopharmaceutical Technology in China, Advances in Large-scale Biopharmaceutical Manufacturing, and many other industry reports. He can be reached at elanger@bioplanassociates.com.

    Survey Methodology
    The 2012 Ninth Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production in the series of annual evaluations by BioPlan Associates, Inc. yields a composite view and trend analysis from 325 responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations (CMOs) in 30 countries. The methodology also included over 150 direct suppliers of materials, services and equipment to this industry. This year’s survey covers such issues as: new product needs, facility budget changes, current capacity, future capacity constraints, expansions, use of disposables, trends and budgets in disposables, trends in downstream purification, quality management and control, hiring issues, and employment. The quantitative trend analysis provides details and comparisons of production by biotherapeutic developers and CMOs. It also evaluates trends over time, and assesses differences in the world’s major markets in the U.S. and Europe.
    Related Searches
    • contract manufacturing organizations
    • Biopharma
    • Manufacturing
    • Development
    Suggested For You
    Oakwood Labs Oakwood Labs
    Mogene Mogene
    Taros Chemicals Taros Chemicals
    Sekisui Sekisui
    Vetio Animal Health Vetio Animal Health
    Recro Gainesville Expands Mfg. Capabilities Recro Gainesville Expands Mfg. Capabilities
    Diverse Products And Technologies Delivered Diverse Products And Technologies Delivered
    PPD Expands Vaccine Development Lab PPD Expands Vaccine Development Lab
    UPM Celebrates 100-Years of Mfg. at Tennessee Site UPM Celebrates 100-Years of Mfg. at Tennessee Site
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    CSSi LifeSciences, BioMARC in Strategic Bio-Mfg. Pact CSSi LifeSciences, BioMARC in Strategic Bio-Mfg. Pact
    Biosimilars Outsourcing and Capacity Biosimilars Outsourcing and Capacity
    Injectables: The New Oral? Injectables: The New Oral?
    Single-use Technology Integral to Advancing Biomanufacturing Single-use Technology Integral to Advancing Biomanufacturing
    2015 in Review: 6 Key Trends Affecting CMOs 2015 in Review: 6 Key Trends Affecting CMOs

    Related Features

    • Analytical Services | Bioanalytical Services | Laboratory Testing | R&D
      Rapid and Data Rich Chromatographic Method Development

      Rapid and Data Rich Chromatographic Method Development

      An overview of what to consider when developing chromatographic methods.
      Daniel Kirschner, Executive Director of Analytical Services, Cambrex - Durham, North Carolina 04.01.21

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21


    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20

    • Biosimilars
      Biosimilar Manufacturing Strategies

      Biosimilar Manufacturing Strategies

      Five steps to competing in a post-patent expiry era.
      George I’ons, Owen Mumford Pharmaceutical Services 09.09.20


    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Biologics, Proteins, Vaccines
      CAR-T Cell Therapy in Clinical Trials

      CAR-T Cell Therapy in Clinical Trials

      The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus
      Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD 06.04.20

    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20


    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20

    • Biosimilars
      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      Biosimilar uptake set to reshape the U.S. market
      Katya Svoboda and Bob Swann, ICON 05.05.20

    • Biologics, Proteins, Vaccines
      CEO Spotlight: Dr. Tae Han Kim

      CEO Spotlight: Dr. Tae Han Kim

      Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic
      Tim Wright, Editor, Contract Pharma 05.05.20

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Alkermes, Merck Enter Clinical Trial And Supply Agreement
    • Ascendia Pharmaceuticals Poised For Expansion
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Chromaflo Technologies Awarded Gold Status CSR Rating by EcoVadis in EMEA
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands 'Beautiful' Fagrance Collection
    Mushrooms Are Key Ingredients in Beauty & Wellness
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login